As of 2024-12-14, the EV/EBITDA ratio of Cue Biopharma Inc (CUE) is -0.86. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CUE's latest enterprise value is 39.07 mil USD. CUE's TTM EBITDA according to its financial statements is -45.22 mil USD. Dividing these 2 quantities gives us the above CUE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 17.0x | 16.0x |
| Forward P/E multiples | 15.4x - 21.2x | 15.7x |
| Fair Price | (10.57) - (11.68) | (10.89) |
| Upside | -1111.0% - -1217.6% | -1141.8% |
| Date | EV/EBITDA |
| 2024-12-12 | -0.86 |
| 2024-12-11 | -0.93 |
| 2024-12-10 | -1.00 |
| 2024-12-09 | -1.00 |
| 2024-12-06 | -0.94 |
| 2024-12-05 | -0.87 |
| 2024-12-04 | -0.84 |
| 2024-12-03 | -1.00 |
| 2024-12-02 | -1.04 |
| 2024-11-29 | -1.11 |
| 2024-11-27 | -1.11 |
| 2024-11-26 | -0.93 |
| 2024-11-25 | -0.88 |
| 2024-11-22 | -0.83 |
| 2024-11-21 | -0.84 |
| 2024-11-20 | -0.93 |
| 2024-11-19 | -0.91 |
| 2024-11-18 | -0.94 |
| 2024-11-15 | -1.14 |
| 2024-11-14 | -1.50 |
| 2024-11-13 | -1.50 |
| 2024-11-12 | -1.78 |
| 2024-11-11 | -2.02 |
| 2024-11-08 | -1.81 |
| 2024-11-07 | -1.89 |
| 2024-11-06 | -1.71 |
| 2024-11-05 | -1.80 |
| 2024-11-04 | -1.49 |
| 2024-11-01 | -1.53 |
| 2024-10-31 | -1.66 |
| 2024-10-30 | -1.85 |
| 2024-10-29 | -1.77 |
| 2024-10-28 | -1.89 |
| 2024-10-25 | -1.47 |
| 2024-10-24 | -1.59 |
| 2024-10-23 | -1.60 |
| 2024-10-22 | -1.64 |
| 2024-10-21 | -1.75 |
| 2024-10-18 | -1.10 |
| 2024-10-17 | -0.96 |
| 2024-10-16 | -0.90 |
| 2024-10-15 | -0.97 |
| 2024-10-14 | -1.10 |
| 2024-10-11 | -1.12 |
| 2024-10-10 | -1.26 |
| 2024-10-09 | -1.09 |
| 2024-10-08 | -1.12 |
| 2024-10-07 | -1.34 |
| 2024-10-04 | -1.03 |
| 2024-10-03 | -0.55 |